This study is conducted to explore the safety and tolerability and plasma pharmacokinetics of NRL001 after single intra-anal dose of 1mL cream at increasing concentrations.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
12
Placebo cream
Cream for single-dose intra-anal application
University Hospital MHAPT Zaritza Johanna
Sofia, Bulgaria
Cmax of NRL001
Time frame: 30 mins, 1, 2, 3, 4, 5, 6, 8 and 12 hours after dosing
AUC of NRL001
Time frame: 30 mins, 1, 2, 3, 4, 5, 6, 8 and 12 hours after dosing
Tolerability of NRL001
Spontaneously reported adverse events will be recorded
Time frame: Up to 12 hours post-dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.